MedTrace Logo

Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia

NCT00755521 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2012-08-10

No results posted yet for this study

Summary

The main of the proposed study is to assess whether the use of the Cox-2 inhibitor Etoricoxib is beneficial for the use in fibromyalgia. We intend to seek whether this medication may improve psychiatric and rheumatologic parameters of the disease.

Conditions

  • Fibromyalgia

Interventions

DRUG

etoricoxib

Treating Fibromyalgia with etoricoxib etoricoxib - 90mg

Sponsors & Collaborators

  • Meir Medical Center

    lead OTHER

Principal Investigators

  • Howard Amital, MD MHA · Meir Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-10-31
Completion
2012-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00755521 on ClinicalTrials.gov